Literature DB >> 25951080

Cerebral palsy research funding from the National Institutes of Health, 2001 to 2013.

Yvonne W Wu1, Alison S Mehravari2, Adam L Numis3, Paul Gross4.   

Abstract

AIM: Cerebral palsy (CP) is a poorly understood disorder with no cure. We determined the landscape of National Institutes of Health (NIH) funding for CP-related research.
METHOD: We searched NIH databases Research Portfolio Online Reporting Tools Expenditures and Results, and Research, Condition, and Disease Categorization for keywords 'cerebral palsy' among all NIH-funded studies, 2001 to 2013. We classified grants by type and area of study.
RESULTS: NIH funding, averaging $30 million per year, supported clinical ($215 million), basic ($187 million), and translational ($26.3 million) CP-related research. Clinical intervention studies comprised 19% of funding, and focused on treatments ($60.3 million), early parent intervention ($2.7 million), and CP prevention ($2.5 million). Among grants that specified gestational age, more funds were devoted to preterm ($166 million) than term infants ($15 million). CP in adulthood was the main focus of 4% of all funding. Annual NIH funding for CP increased steadily over the study period from $3.6 to $66.7 million. However, funding for clinical intervention studies peaked in 2008, and has since decreased.
INTERPRETATION: Additional research funds are needed to improve the treatment and prevention of CP. Topics that have been relatively underfunded include clinical interventions, prevention, and term infants and adults with CP.
© 2015 Mac Keith Press.

Entities:  

Mesh:

Year:  2015        PMID: 25951080     DOI: 10.1111/dmcn.12789

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  9 in total

1.  Funding for cerebral palsy research in Australia, 2000-2015: an observational study.

Authors:  D L Herbert; A G Barnett; R White; I Novak; N Badawi
Journal:  BMJ Open       Date:  2016-10-24       Impact factor: 2.692

2.  Beneficial Effects of Childhood Selective Dorsal Rhizotomy in Adulthood.

Authors:  T S Park; Caleb Edwards; Jenny L Liu; Deanna M Walter; Matthew B Dobbs
Journal:  Cureus       Date:  2017-03-05

Review 3.  Neurologic Correlates of Gait Abnormalities in Cerebral Palsy: Implications for Treatment.

Authors:  Joanne Zhou; Erin E Butler; Jessica Rose
Journal:  Front Hum Neurosci       Date:  2017-03-17       Impact factor: 3.169

4.  Scalp acupuncture for children with cerebral palsy: A protocol for a systematic review.

Authors:  Go-Eun Lee; Pei-Ting Lee; Ni Ran; Jianwei Zhou
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

5.  The National Institutes of Health funding for clinical research applying machine learning techniques in 2017.

Authors:  Amarnath R Annapureddy; Suveen Angraal; Cesar Caraballo; Alyssa Grimshaw; Chenxi Huang; Bobak J Mortazavi; Harlan M Krumholz
Journal:  NPJ Digit Med       Date:  2020-01-31

6.  Cerebral Palsy Research Network Clinical Registry: Methodology and Baseline Report.

Authors:  Paul Gross; Mary Gannotti; Amy Bailes; Susan D Horn; Jacob Kean; Unni G Narayanan; Jerry Oakes; Garey Noritz
Journal:  Arch Rehabil Res Clin Transl       Date:  2020-04-19

7.  Motivators and barriers to research participation for individuals with cerebral palsy and their families.

Authors:  Kristina M Zvolanek; Vatsala Goyal; Alexandra Hruby; Carson Ingo; Theresa Sukal-Moulton
Journal:  PLoS One       Date:  2022-01-26       Impact factor: 3.240

8.  Short-term causal effects of common treatments in ambulatory children and young adults with cerebral palsy: three machine learning estimates.

Authors:  Michael H Schwartz; Andrew J Ries; Andrew G Georgiadis
Journal:  Sci Rep       Date:  2022-05-12       Impact factor: 4.996

9.  Reduced wrist flexor H-reflex excitability is linked with increased wrist proprioceptive error in adults with cerebral palsy.

Authors:  S Shekar Dukkipati; Sarah J Walker; Michael P Trevarrow; Morgan Busboom; Sarah E Baker; Max J Kurz
Journal:  Front Neurol       Date:  2022-08-09       Impact factor: 4.086

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.